Prognostic Significance of Hemoglobin/Prognostic Nutritional Index and Hemoglobin/Red Blood Cell Distribution in Rectal Cancer.
Journal
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
ISSN: 2148-5607
Titre abrégé: Turk J Gastroenterol
Pays: Turkey
ID NLM: 9515841
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
pubmed:
14
12
2022
medline:
3
3
2023
entrez:
13
12
2022
Statut:
ppublish
Résumé
We aimed to investigate the effect of hemoglobin/prognostic nutritional index and hemoglobin/red blood cell distribution, which are indicators of inflammation and nutrition, on prognosis and survival in patients with rectal cancer. The retrospective study reviewed medical records of 138 patients with rectal cancer who were followed up between 2010 and 2021. The effects of hemoglobin/red blood cell distribution, hemoglobin/prognostic nutritional index, tumor stage, and lymph node status on survival and prognosis were evaluated using univariate and multivariate analyses. Overall survival and disease-free survival were calculated for both groups. Survival and prognosis were found to be significantly better in nonanemic patients with the hemoglobin/prognostic nutritional index higher than the cut-off value than in anemic patients with a normal or lower hemoglobin/prognostic nutritional index. Similarly, survival and prognosis were found to be significantly better in nonanemic patients with a hemoglobin/red blood cell distribution higher than the cut-off value than in anemic patients with a normal or lower hemoglobin/red blood cell distribution. The results indicated that nutrition and inflammatory markers have independent prognostic significance in rectal cancer. These markers are simple, inexpensive, and useful biomarkers commonly used in clinical practice, and they were found to predict overall survival and disease-free survival independently.
Sections du résumé
BACKGROUND
We aimed to investigate the effect of hemoglobin/prognostic nutritional index and hemoglobin/red blood cell distribution, which are indicators of inflammation and nutrition, on prognosis and survival in patients with rectal cancer.
METHODS
The retrospective study reviewed medical records of 138 patients with rectal cancer who were followed up between 2010 and 2021. The effects of hemoglobin/red blood cell distribution, hemoglobin/prognostic nutritional index, tumor stage, and lymph node status on survival and prognosis were evaluated using univariate and multivariate analyses. Overall survival and disease-free survival were calculated for both groups.
RESULTS
Survival and prognosis were found to be significantly better in nonanemic patients with the hemoglobin/prognostic nutritional index higher than the cut-off value than in anemic patients with a normal or lower hemoglobin/prognostic nutritional index. Similarly, survival and prognosis were found to be significantly better in nonanemic patients with a hemoglobin/red blood cell distribution higher than the cut-off value than in anemic patients with a normal or lower hemoglobin/red blood cell distribution.
CONCLUSION
The results indicated that nutrition and inflammatory markers have independent prognostic significance in rectal cancer. These markers are simple, inexpensive, and useful biomarkers commonly used in clinical practice, and they were found to predict overall survival and disease-free survival independently.
Identifiants
pubmed: 36511609
doi: 10.5152/tjg.2022.22203
pmc: PMC10081009
doi:
Substances chimiques
Hemoglobins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
128-134Références
Ann Surg. 2018 Mar;267(3):527-531
pubmed: 27984214
Gut Liver. 2011 Dec;5(4):460-7
pubmed: 22195244
Medicine (Baltimore). 2015 Mar;94(10):e612
pubmed: 25761184
Surg Today. 2012 Jun;42(6):532-5
pubmed: 22139087
Curr Opin Clin Nutr Metab Care. 2009 May;12(3):223-6
pubmed: 19318937
World J Gastroenterol. 2014 Oct 21;20(39):14450-4
pubmed: 25339831
Br J Surg. 2011 Feb;98(2):268-74
pubmed: 20960457
Gastroenterology. 2010 Jun;138(6):2101-2114.e5
pubmed: 20420949
PLoS One. 2013 Nov 11;8(11):e80240
pubmed: 24244659
Biomed Res Int. 2021 Jan 09;2021:8729869
pubmed: 33506035
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468
Medicine (Baltimore). 2016 Dec;95(49):e5540
pubmed: 27930549
Eur J Cardiothorac Surg. 2014 Jan;45(1):108-13
pubmed: 23711463
PLoS One. 2020 Aug 24;15(8):e0237947
pubmed: 32833961
Int J Cancer. 2019 Oct 15;145(8):2282-2291
pubmed: 30868576
Oncotarget. 2016 Jul 5;7(27):42650-42660
pubmed: 27223088
Indian Heart J. 2012 Jul-Aug;64(4):380-7
pubmed: 22929821
World J Surg. 2013 Nov;37(11):2688-92
pubmed: 23884382
Int J Cancer. 2014 May 15;134(10):2403-13
pubmed: 24122750
Int J Clin Exp Med. 2015 Mar 15;8(3):4228-35
pubmed: 26064334
World J Gastroenterol. 2014 Aug 14;20(30):10537-44
pubmed: 25132773
Tumour Biol. 2015 May;36(5):3389-97
pubmed: 25527156
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Adv Ther. 2020 Mar;37(3):1145-1155
pubmed: 32002809
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Ann Surg Oncol. 2013 Aug;20(8):2647-54
pubmed: 23463091
Gastroenterology. 2020 Jul;159(1):241-256.e13
pubmed: 32247020
Cancer Manag Res. 2020 Sep 18;12:8589-8597
pubmed: 32982451
Tumour Biol. 2016 Mar;37(3):3277-83
pubmed: 26438061
Anticancer Res. 2014 Aug;34(8):4223-9
pubmed: 25075051